Business Wire

SLATE-ASSET-MANAGEMENT

Share
Slate Asset Management Acquires the World Seafood Center in Oslo for Approximately NOK 1.3 Billion

Slate Asset Management (“Slate”), a global alternative investment platform targeting real assets, today announced that it has acquired the World Seafood Center, a state-of-the-art, new build seafood refrigeration and distribution facility, located in one of the most prominent and well-connected logistics hubs, Oslo Airport City, in Gardermoen, Norway, for approximately NOK 1.3 billion. The acquisition further scales Slate’s portfolio of essential real estate assets in Europe and expands Slate’s real estate footprint in the Nordics.

The seafood industry is the second largest and growing export industry in Norway and benefits from strong demographic tailwinds that are driving high demand for seafood industrial space in the region. The World Seafood Center is a 55,000 square meter facility strategically located in the rapidly developing Gardermoen region within Oslo Airport City with immediate access to main transport networks to Europe and the overseas markets in Asia and America. The property is let to some of the largest seafood tenants in the world under long lease terms indexed with CPI, which are expected to provide stable and resilient cash flows. The facility derives 100% of its energy supply from green and renewable sources and is equipped with robotics and artificial intelligence technologies, which further contribute to its high levels of operating and energy efficiency.

“We are pleased to be increasing our exposure to European essential real estate with the acquisition of this premier cold storage and distribution facility,” said Sven Vollenbruch, Managing Director at Slate. “The World Seafood Center has established itself as a critical part of the food supply chain globally, providing consumers across Europe, America, and Asia with access to high-quality Norwegian seafood. As global demand for sustainable seafood continues to grow, we look forward to working together with the leading tenants at the World Seafood Center to further enhance the quality, efficiency, and resiliency of this facility, ensuring it remains a major seafood export hub for years to come.”

One of the property’s largest tenants, Mowi, is the world’s largest seafood company listed on the Oslo Stock Exchange. Mowi controls approximately 20% of global seafood distribution, selling their products in over 70 countries and supplying eight million meals around the world each day. As the world’s largest farmer of Atlantic salmon – one of the most eco-efficient and sustainable forms of animal protein available – Mowi has been ranked the most sustainable protein producer by the Coller FAIRR Protein Producer Index for five years in a row.

Slate has been an active investor in the European real estate market since 2016 and has transacted on approximately 1,000 commercial properties across 6 countries in the region. Today, Slate has a portfolio of around 500 essential real estate assets. Slate’s European real estate strategy is focused on acquiring, owning, and operating cash yielding, essential real estate assets, such as grocery; pharma or other healthcare services assets; and affiliated warehouses and logistics assets.

The seller of the property is Oslo Airport City (“OAC”), which represents today's most important destination development in Norway, in the form of a multicore, transit-oriented hub, where innovative, economically sustainable, and urban qualities become regional "growth drivers" in this long-term commitment to infrastructure. Currently OAC has over 76,000 square meters of logistics space under construction, with zoning to build up to 1 million square meters.

Pareto Securities, Schjødt, CBRE, KPMG, BER, and agradblue – part of Westbridge – advised Slate and Colliers, Thommessen, and Vedal advised OAC on this transaction, which is expected to close at the end of June 2024.

About Slate Asset Management
Slate Asset Management is a global alternative investment platform. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate’s platform focuses on four areas of real assets, including real estate equity, real estate credit, real estate securities, and infrastructure. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities. Visit slateam.com to learn more, and follow Slate Asset Management on LinkedIn, X (Twitter), and Instagram.

About Oslo Airport City
Oslo Airport City is a destination developer that aims to build approximately 1 million m2 of commercial space, including logistics facilities, commerce, office spaces, industrial and processing, services, hotels, conference facilities and recreational spaces. Visit us at osloairportcity.no and on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240610414467/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye